REGENERON PHARMACEUTICALS, INC. Proceeds from Common Stock Issued
REGENERON PHARMACEUTICALS, INC. (REGN) reported Proceeds from Common Stock Issued of $212.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-07-30
- REGENERON PHARMACEUTICALS, INC. proceeds from issuance of common stock for the quarter ending 2026-06-30 was $49.20M, a 56.19% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. proceeds from issuance of common stock for the quarter ending 2026-03-31 was $163.10M, a 169.14% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. proceeds from issuance of common stock for the quarter ending 2025-12-31 was $503.50M, a 453.91% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $40.30M, a 84.18% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. proceeds from issuance of common stock for fiscal 2025 was $635.90M, a 56.60% decline from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. proceeds from issuance of common stock for fiscal 2024 was $1.47B, a 27.92% increase from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. proceeds from issuance of common stock for fiscal 2023 was $1.15B, a 24.61% decline from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. proceeds from issuance of common stock for fiscal 2022 was $1.52B, a 9.14% decline from fiscal 2021.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 3 month as first filed | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 6 month as first filed | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 9 month as first filed | Proceeds from Issuance of Common Stock 12 month | Proceeds from Issuance of Common Stock 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $49.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $212.30M 10-Q · filed 2026-07-30 | $715.80M derived: sum of 3 quarters · filed 2026-07-30 | $756.10M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $163.10M 10-Q · filed 2026-04-29 | $666.60M derived: sum of 2 quarters · filed 2026-04-29 | $706.90M derived: sum of 3 quarters · filed 2026-04-29 | $738.40M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $503.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $543.80M derived: sum of 2 quarters · filed 2026-02-04 | $575.30M derived: sum of 3 quarters · filed 2026-07-30 | $635.90M 10-K · filed 2026-02-04 | ||||
| 2025-09-30 | $40.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $71.80M derived: sum of 2 quarters · filed 2026-07-30 | $132.40M 10-Q · filed 2025-10-28 | $223.30M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $31.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $92.10M 10-Q · filed 2026-07-30 | $183.00M derived: sum of 3 quarters · filed 2026-07-30 | $437.70M derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $60.60M 10-Q · filed 2026-04-29 | $151.50M derived: sum of 2 quarters · filed 2026-04-29 | $406.20M derived: sum of 3 quarters · filed 2026-04-29 | $843.80M derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2024-12-31 | $90.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $345.60M derived: sum of 2 quarters · filed 2026-02-04 | $783.20M derived: sum of 3 quarters · filed 2026-02-04 | $1.47B 10-K · filed 2026-02-04 | ||||
| 2024-09-30 | $254.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $692.30M derived: sum of 2 quarters · filed 2025-10-28 | $1.37B 10-Q · filed 2025-10-28 | $1.68B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-06-30 | $437.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | $1.12B 10-Q · filed 2025-08-01 | $1.42B derived: sum of 3 quarters · filed 2026-02-04 | $1.69B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-03-31 | $682.10M 10-Q · filed 2025-04-29 | $983.10M derived: sum of 2 quarters · filed 2026-02-04 | $1.25B derived: sum of 3 quarters · filed 2026-02-04 | $1.34B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2023-12-31 | $301.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $569.60M derived: sum of 2 quarters · filed 2026-02-04 | $660.30M derived: sum of 3 quarters · filed 2026-02-04 | $1.15B 10-K · filed 2026-02-04 | ||||
| 2023-09-30 | $268.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $359.30M derived: sum of 2 quarters · filed 2024-10-31 | $844.50M 10-Q · filed 2024-10-31 | $1.22B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-06-30 | $90.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $575.90M 10-Q · filed 2024-08-01 | $948.50M derived: sum of 3 quarters · filed 2025-02-05 | $1.27B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-03-31 | $485.20M 10-Q · filed 2024-05-02 | $857.80M derived: sum of 2 quarters · filed 2025-02-05 | $1.18B derived: sum of 3 quarters · filed 2025-02-05 | $1.48B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2022-12-31 | $372.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-05 | $691.10M derived: sum of 2 quarters · filed 2025-02-05 | $997.90M derived: sum of 3 quarters · filed 2025-02-05 | $1.52B 10-K · filed 2025-02-05 | ||||
| 2022-09-30 | $318.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $625.30M derived: sum of 2 quarters · filed 2023-11-02 | $1.15B 10-Q · filed 2023-11-02 | $1.69B derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-06-30 | $306.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $828.40M 10-Q · filed 2023-08-03 | $1.37B derived: sum of 3 quarters · filed 2024-02-05 | $2.19B derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-03-31 | $521.60M 10-Q · filed 2023-05-04 | $1.06B derived: sum of 2 quarters · filed 2024-02-05 | $1.89B derived: sum of 3 quarters · filed 2024-02-05 | $2.10B derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2021-12-31 | $542.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-05 | $1.36B derived: sum of 2 quarters · filed 2024-02-05 | $1.58B derived: sum of 3 quarters · filed 2024-02-05 | $1.67B 10-K · filed 2024-02-05 | ||||
| 2021-09-30 | $821.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.03B derived: sum of 2 quarters · filed 2022-11-03 | $1.13B 10-Q · filed 2022-11-03 | $1.23B derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-06-30 | $213.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $308.20M 10-Q · filed 2022-08-03 | $412.30M derived: sum of 3 quarters · filed 2023-02-06 | $715.40M derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-03-31 | $95.00M 10-Q · filed 2022-05-04 | $199.10M derived: sum of 2 quarters · filed 2023-02-06 | $502.20M derived: sum of 3 quarters · filed 2023-02-06 | $1.86B derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2020-12-31 | $104.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-06 | $407.20M derived: sum of 2 quarters · filed 2023-02-06 | $1.76B derived: sum of 3 quarters · filed 2023-02-06 | $2.58B 10-K · filed 2023-02-06 | ||||
| 2020-09-30 | $303.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $1.66B derived: sum of 2 quarters · filed 2021-11-04 | $2.47B 10-Q · filed 2021-11-04 | $2.52B derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-06-30 | $1.36B derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $2.17B 10-Q · filed 2021-08-05 | $2.22B derived: sum of 3 quarters · filed 2022-02-07 | $2.22B derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-03-31 | $811.40M 10-Q · filed 2021-05-06 | $859.70M derived: sum of 2 quarters · filed 2022-02-07 | $868.10M derived: sum of 3 quarters · filed 2022-02-07 | $882.60M derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2019-12-31 | $48.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-07 | $56.70M derived: sum of 2 quarters · filed 2022-02-07 | $71.20M derived: sum of 3 quarters · filed 2022-02-07 | $211.80M 10-K · filed 2022-02-07 | ||||
| 2019-09-30 | $8.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $22.90M derived: sum of 2 quarters · filed 2020-11-05 | $163.50M 10-Q · filed 2020-11-05 | $190.60M derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2019-06-30 | $14.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $155.10M 10-Q · filed 2020-08-05 | $182.20M derived: sum of 3 quarters · filed 2021-02-08 | $235.50M derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2019-03-31 | $140.60M 10-Q · filed 2020-05-05 | $167.70M derived: sum of 2 quarters · filed 2021-02-08 | $221.00M derived: sum of 3 quarters · filed 2021-02-08 | $241.70M derived: sum of 4 quarters · filed 2021-02-08 | ||||
| 2018-12-31 | $27.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-08 | $80.40M derived: sum of 2 quarters · filed 2021-02-08 | $101.10M derived: sum of 3 quarters · filed 2021-02-08 | $114.50M 10-K · filed 2021-02-08 | ||||
| 2018-09-30 | $53.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $74.00M derived: sum of 2 quarters · filed 2019-11-05 | $87.40M 10-Q · filed 2019-11-05 | $87.41M 10-Q · filed 2018-11-06 | $100.71M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-06-30 | $20.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $34.10M 10-Q · filed 2019-08-06 | $34.07M 10-Q · filed 2018-08-02 | $47.41M derived: sum of 3 quarters · filed 2020-02-07 | $85.61M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2018-03-31 | $13.40M 10-Q · filed 2019-05-07 | $13.43M 10-Q · filed 2018-05-03 | $26.71M derived: sum of 2 quarters · filed 2020-02-07 | $64.91M derived: sum of 3 quarters · filed 2020-02-07 | $236.93M derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2017-12-31 | $13.31M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | $51.51M derived: sum of 2 quarters · filed 2020-02-07 | $223.53M derived: sum of 3 quarters · filed 2020-02-07 | $240.20M 10-K · filed 2020-02-07 | $240.21M 10-K · filed 2018-02-08 | |||
| 2017-09-30 | $38.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $210.22M derived: sum of 2 quarters · filed 2018-11-06 | $226.89M 10-Q · filed 2018-11-06 | $263.81M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-06-30 | $172.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $188.69M 10-Q · filed 2018-08-02 | $225.62M derived: sum of 3 quarters · filed 2019-02-07 | $251.79M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-03-31 | $16.67M 10-Q · filed 2018-05-03 | $53.60M derived: sum of 2 quarters · filed 2019-02-07 | $79.77M derived: sum of 3 quarters · filed 2019-02-07 | $104.07M derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2016-12-31 | $36.92M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | $63.09M derived: sum of 2 quarters · filed 2019-02-07 | $87.40M derived: sum of 3 quarters · filed 2019-02-07 | $126.70M 10-K · filed 2019-02-07 | $126.74M 10-K · filed 2017-02-09 | |||
| 2016-09-30 | $26.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $50.47M derived: sum of 2 quarters · filed 2017-11-08 | $89.78M 10-Q · filed 2017-11-08 | $145.71M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-06-30 | $24.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $63.61M 10-Q · filed 2017-08-03 | $119.54M derived: sum of 3 quarters · filed 2018-02-08 | $154.14M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-03-31 | $39.30M 10-Q · filed 2017-05-04 | $95.24M derived: sum of 2 quarters · filed 2018-02-08 | $129.84M derived: sum of 3 quarters · filed 2018-02-08 | $169.39M derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2015-12-31 | $55.94M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $90.53M derived: sum of 2 quarters · filed 2018-02-08 | $130.09M derived: sum of 3 quarters · filed 2018-02-08 | $206.36M 10-K · filed 2018-02-08 | ||||
| 2015-09-30 | $34.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | $74.15M derived: sum of 2 quarters · filed 2016-11-04 | $150.42M 10-Q · filed 2016-11-04 | $195.66M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-06-30 | $39.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $115.83M 10-Q · filed 2016-08-04 | $161.07M derived: sum of 3 quarters · filed 2017-02-09 | $178.81M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-03-31 | $76.27M 10-Q · filed 2016-05-05 | $121.51M derived: sum of 2 quarters · filed 2017-02-09 | $139.26M derived: sum of 3 quarters · filed 2017-02-09 | $147.28M derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2014-12-31 | $45.24M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $62.99M derived: sum of 2 quarters · filed 2017-02-09 | $71.00M derived: sum of 3 quarters · filed 2017-02-09 | $126.05M 10-K · filed 2017-02-09 | ||||
| 2014-09-30 | $17.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $25.76M derived: sum of 2 quarters · filed 2015-11-04 | $80.80M 10-Q · filed 2015-11-04 | $96.48M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2014-06-30 | $8.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $63.06M 10-Q · filed 2015-08-04 | $78.73M derived: sum of 3 quarters · filed 2016-02-11 | $86.15M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2014-03-31 | $55.04M 10-Q · filed 2015-05-07 | $70.72M derived: sum of 2 quarters · filed 2016-02-11 | $78.14M derived: sum of 3 quarters · filed 2016-02-11 | $99.47M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2013-12-31 | $15.68M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $23.09M derived: sum of 2 quarters · filed 2016-02-11 | $44.43M derived: sum of 3 quarters · filed 2016-02-11 | $57.39M 10-K · filed 2016-02-11 | ||||
| 2013-09-30 | $7.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $28.75M derived: sum of 2 quarters · filed 2014-11-04 | $41.72M 10-Q · filed 2014-11-04 | $56.83M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-06-30 | $21.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $34.30M 10-Q · filed 2014-08-05 | $49.41M derived: sum of 3 quarters · filed 2015-02-12 | $58.22M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-03-31 | $12.96M 10-Q · filed 2014-05-08 | $28.07M derived: sum of 2 quarters · filed 2015-02-12 | $36.88M derived: sum of 3 quarters · filed 2015-02-12 | $44.69M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2012-12-31 | $15.11M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $23.92M derived: sum of 2 quarters · filed 2015-02-12 | $31.72M derived: sum of 3 quarters · filed 2015-02-12 | $63.55M 10-K · filed 2015-02-12 | ||||
| 2012-09-30 | $8.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $16.61M derived: sum of 2 quarters · filed 2013-11-05 | $48.44M 10-Q · filed 2013-11-05 | $51.89M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2012-06-30 | $7.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $39.63M 10-Q · filed 2013-08-06 | $43.08M derived: sum of 3 quarters · filed 2014-02-13 | $54.72M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2012-03-31 | $31.83M 10-Q · filed 2013-05-03 | $35.28M derived: sum of 2 quarters · filed 2014-02-13 | $46.91M derived: sum of 3 quarters · filed 2014-02-13 | $61.01M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2011-12-31 | $3.45M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13 | $15.09M derived: sum of 2 quarters · filed 2014-02-13 | $29.18M derived: sum of 3 quarters · filed 2014-02-13 | $43.59M 10-K · filed 2014-02-13 | $18.51M 10-K · filed 2012-02-21 | |||
| 2011-09-30 | $11.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $25.73M derived: sum of 2 quarters · filed 2012-10-24 | $40.13M 10-Q · filed 2012-10-24 | $23.99M 10-Q · filed 2011-10-27 | $226.96M derived: sum of 4 quarters · filed 2013-02-15 | |||
| 2011-06-30 | $14.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | $28.50M 10-Q · filed 2012-07-25 | $23.75M 10-Q · filed 2011-07-28 | $215.33M derived: sum of 3 quarters · filed 2013-02-15 | $217.03M derived: sum of 4 quarters · filed 2013-02-15 | |||
| 2011-03-31 | $14.41M 10-Q · filed 2012-04-26 | $13.34M 10-Q · filed 2011-05-03 | $201.23M derived: sum of 2 quarters · filed 2013-02-15 | $202.93M derived: sum of 3 quarters · filed 2013-02-15 | $205.77M derived: sum of 4 quarters · filed 2013-02-15 | |||
| 2010-12-31 | $186.83M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $188.52M derived: sum of 2 quarters · filed 2013-02-15 | $191.36M derived: sum of 3 quarters · filed 2013-02-15 | $200.59M 10-K · filed 2013-02-15 | $196.79M 10-K · filed 2011-02-17 | |||
| 2010-09-30 | $1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $4.53M derived: sum of 2 quarters · filed 2011-10-27 | $13.76M 10-Q · filed 2011-10-27 | $17.73M derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-06-30 | $2.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $12.06M 10-Q · filed 2011-07-28 | $16.04M derived: sum of 3 quarters · filed 2012-02-21 | $18.96M derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-03-31 | $9.23M 10-Q · filed 2011-05-03 | $13.20M derived: sum of 2 quarters · filed 2012-02-21 | $16.12M derived: sum of 3 quarters · filed 2012-02-21 | |||||
| 2009-12-31 | $3.97M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | $6.89M derived: sum of 2 quarters · filed 2012-02-21 | $8.60M 10-K · filed 2012-02-21 | |||||
| 2009-09-30 | $2.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $4.63M 10-Q · filed 2010-10-28 | ||||||
| 2009-06-30 | $1.71M 10-Q · filed 2010-07-28 | |||||||
| 2008-12-31 | $7.95M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |